Zoom-Zoom+Black contrastBlue contrastWhite contrast

Italiano

How to use the speech recognition tool?

Back

Hydroxychloroquine hitting the headlines - retinal considerations

 

ERN-EYE experts published an editorial in the scientific journal "Eye" about Hydroxychloroquine :
Downes SM, Leroy BP, Sharma SM, Sivaprasad S, Dollfus H. Hydroxychloroquine hitting the headlines - retinal considerations. Eye [Internet]. 19 may 2020; Available : https://doi.org/10.1038/s41433-020-0934-9

"Hydroxychloroquine (HCQ) is currently used widely for the treatment of rheumatological and dermatological disorders. HCQ is generally used in preference to chloroquine (CQ) due to its better safety profile with fewer side effects. Recently, these two 4-aminoquinolones have made headline news as potential treatments for individuals with SARS-CoV-2 infection and have also been proposed as a prophylactic medication to prevent COVID-19. In this editorial, we highlight the importance of careful use of these drugs, because of their potential to cause an irreversible toxic retinopathy."

 

Read the article of ERN-EYE experts

 

Subscribe to our mailing list

* indicates required

This ERN is supported by: